CompletedNCT05212402Updated Nov 1, 2022

Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

An interventional study of Cannabinol and Placebo in Healthy and Safety Issues, sponsored by University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by University of South Carolina · Not applicable, Interventional, and Other

Phase: Not applicable
Study type: Interventional
Enrollment: 56
Allocation: Randomized
Ages: 18 Years to 55 Years
Sex: All

Study summary

The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy adults.

Read the detailed description

Cannabis contains several phyto-cannabinoids among which Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are most widely known. THC is the main compound responsible for the psychoactive properties and also deemed responsible for several side-effects associated with cannabis. CBD, on the other hand, is not a strong cannabinoid receptor agonist and lacks psychotropic activity. However, due to its affinity for several other target sites, it is being studied for potential pharmacological properties. The diverse range of interactions at different receptor sites in the human body is believed to be responsible for therapeutic efficacy of CBD in treating kidney fibrosis, metabolic syndrome, anorexia, obesity, amelioration of osteoarthritis as well as several other musculoskeletal diseases. Recent research has also explored the use of CBD to relieve stress and depression, likely due to its agonistic influence on the 5-HT3 receptors as well as improving hippocampal neural growth and development. CBD has also been studied for its anti-oxidant activity, deemed on-par to that of Vitamin C in laboratory studies. The effect of CBD on inflammation and the immune system has been studied. The sedative effects of CBD have been investigated for the potential use of CBD as an anxiolytic and to improve mood as well as sleep. Recent studies have also explored the analgesic and pain-relieving properties of CBD, making it a suitable candidate that needs further investigations. Interestingly, a recent systematic review explored the use of CBD in viral diseases, with several pre-clinical studies indicating CBD as an effective candidate against viral disease. With the spread of the coronavirus disease (COVID-19) pandemic, there has been a strong interest in developing therapies to eliminate or reduce the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 uses Angiotensin Converting Enzyme (ACE) receptors to gain entry into the human body and penetrate the respiratory system. In a recent in vitro study, pretreatment with CBD in cells expressing ACE-2 receptor was effective in inhibiting the replication of SARS-CoV-2 in those cells. This is an interesting finding where further research is needed to study the influence of CBD consumption on ACE activity. Several studies of CBD safety have demonstrated lack of any safety concerns over a range of different doses. A recent safety study of CBD by Bergamaschi et al. demonstrated absence of any influence on the central nervous system, vital signs or mood changes as well as lack of any side effect observed for doses up to 1500 mg/day (orally) or 30 mg/day (intravenously).It has been hypothesized that the trace amounts of THC present within the CBD extract could potentially be responsible for any side-effects. Therefore, CBD is considered very safe for human consumption in the dose being tested in this study (\<200mg/day). Additional clinical research is required to confirm and support therapeutic use of CBD for being effective in modulating ACE expression, mood, stress, anti-inflammatory, antioxidant, immunomodulating, sedative \& anxiolytic, analgesic, pain relieving and anti-viral therapeutic claims. This research will also help to understand any safety issues with the long-term regular use of CBD on healthy adults. Therefore, this prospective, randomized, double-blind, placebo controlled study will be conducted to explore the physiologic, biochemical, and psychometric impacts of a brand-specific hemp-derived CBD product in healthy adults.

Conditions studied

Healthy
Safety Issues

In context

Lead sponsor

University of South Carolina is the lead sponsor of 196 studies on the registry; 42 are open to participants now.

Browse University of South Carolina studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 55 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

body mass index of 19.0 to 34.9 kg/m2 (normal weight through Class I obesity)
Agree to refrain from alcohol consumption for at least 48 hours prior to each visit.
Willing to practice acceptable measures of birth control and sexually transmitted infections prevention by using double-barrier contraceptive measures (both males and females) throughout the study duration.
Willing and able to agree to the requirements and restrictions of this study including fasting before blood draw on all visits for laboratory assessment.
Willing to give voluntary consent, be able to understand and read the questionnaires, carry out all study-related procedures, communicate effectively with the study staff, and agree to allow any study related evaluations.

Exclusion criteria

Exclusion Criteria:

Have a known sensitivity or allergy to any of the investigational products or their ingredients.
Female participants who are lactating, pregnant or planning to become pregnant during the study as confirmed at the baseline (visit 2) or male participants of reproductive potential in a heterosexual relationship planning a pregnancy as confirmed at the baseline visit.
Documented medical history of immune disorder (such as Human immunodeficiency Virus/Acquired immunodeficiency syndrome), hepatitis B or hepatitis C, or reported immune disorder diagnosis.
Active psychiatric disorder requiring hospitalization within the 12 months prior to screening or currently on medication(s) to treat any psychiatric disorder(s).
Any cognitive impairment that would, in the opinion of the Investigator, preclude study participation or compliance with study procedures (e.g., Alzheimer's, dementia).
History of malignancy or those with any first-degree relatives with a history of cancer (e.g., familial cancer disorders) within 5 years.
History of clinically significant cardiovascular, respiratory, renal, cerebrovascular, metabolic, pulmonary, gastrointestinal, neurological, hematological, autoimmune, lymphatic, psychiatric, chronic pain and sleep disorders, hepatobiliary (with the exception of Gilbert's syndrome or asymptomatic gallstones) or endocrine disorders, including individuals with Type I or Type II diabetes, or other clinically significant medical condition that, in the opinion of the Investigator, may preclude safe study participation.
Participants with controlled or uncontrolled hypertension including stage 1 hypertension (systolic blood pressure ≥129 mmHg and diastolic blood pressure ≥89 mmHg).
Participants who are on medications as prescribed for any of the aforementioned exclusionary criteria. Participants on stable dose of thyroid medication (no dosage changes within last 3 months) are acceptable.
Consumption of prescription or non-prescription: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, barbiturates, cocaine, ethanol, selective serotonin reuptake inhibitor, protease inhibitors, warfarin, sildenafil, theophylline, tricyclic antidepressants and any other medications
Receipt or use of an investigational product in another research study within 30 days or 5 half lives (whichever is longer) prior to baseline (visit 2) or currently participating in another study
Receipt or use of an investigational product in another research study within 30 days or 5 half lives (whichever is longer) prior to baseline (visit 2) or currently participating in another study
Current or recent use (within one month prior to visit 2) of cannabis (e.g., marijuana) or cannabis related products (e.g., CBD) in any ingestible or inhalable forms.
Positive urine drug test for THC or drugs of abuse (Amphetamine, cocaine, marijuana, methamphetamine, and opiates) at baseline (visit 2).
Safety blood tests at screening more than 2 times the upper limit of normal (ULN) for liver or kidney function tests.
Safety blood tests at screening more than 2 times the upper limit of normal (ULN) for liver or kidney function tests.
Fasting blood glucose of ≥160 mg/dL (after a repeat that confirms the original result) at screening.
Any other condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.

Study design

Phase: Not applicable
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Investigator, Outcomes assessor)
Enrollment: 56 participants (actual)

Study arms

Experimental
Test Product
28 participants will be given the test product (TP)
Dietary Supplement: Cannabinol
Placebo comparator
Placebo
28 participants will be given the placebo product.
Other: Placebo

Interventions

Dietary supplementCannabinol
Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
OtherPlacebo
Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.

What researchers measure

Primary outcomes

Changes in angiotensin-renin converting enzyme (ACE)
To determine if the test product (TP) has any effect on the activity of angiotensin-renin converting enzyme (ACE) compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in white blood cell count
To determine if the TP has an impact on white blood cell count compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in red blood cell count
To determine if the TP has an impact on red blood cell count compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in hemoglobin
To determine if the TP has an impact on hemoglobin compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in hematocrit
To determine if the TP has an impact on hematocrit compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in mean corpuscular volume
To determine if the TP has an impact on mean corpuscular volume compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in mean corpuscular hemoglobin concentration
To determine if the TP has an impact on mean corpuscular hemoglobin concentration compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in red blood cell distribution width
To determine if the TP has an impact on red blood cell distribution width concentration compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in platelet count
To determine if the TP has an impact on platelet count compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in mean platelet volume
To determine if the TP has an impact on mean platelet volume compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in absolute and relative neutrophils
To determine if the TP has an impact on absolute and relative neutrophils compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in absolute and relative lymphocytes
To determine if the TP has an impact on absolute and relative lymphocytes compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in absolute and relative monocytes
To determine if the TP has an impact on absolute and relative monocytes compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in absolute and relative eosinophils
To determine if the TP has an impact on absolute and relative eosinophils compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in absolute and relative basophils
To determine if the TP has an impact on absolute and relative basophils compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in TNF-alpha
To determine if the TP has an impact on TNF-alpha compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in interleukin-6
To determine if the TP has an impact on interleukin-6 compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in interleukin-10
To determine if the TP has an impact on interleukin-10 compared to placebo
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in cold and flu prevalence
To determine if the TP has an impact on number of days of lost productivity (days taken off from work or school) due to cold/flu symptoms compared to placebo
Time frame: Baseline, Month 3
Changes in subjective stress levels
To determine if the TP has an impact on stress levels assessed by Cohen's perceived stress scale compared to placebo. The minimum value is 0 and the maximum value is 40. Higher scores mean a worse outcome.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in sleep quality
To determine if the TP has an impact on sleep quality assessed by Pittsburgh Sleep Quality Index compared to placebo. The minimum score is 0 and the maximum score is 40. Higher scores mean a worse outcome.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in total mood disturbances
To determine if the TP has an impact on total mood disturbance assessed by the Profile of Mood States (POMS) compared to placebo The total mood is calculated by adding the negative subscales (tension, depression, fatigue, confusion, and anger) subtracting the positive subscales (vigor, esteem-related affect).
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in fatigue-inertia
To determine if the TP has an impact on fatigue-inertia (POMS sub-score) compared to placebo. Min 0, Max 28, higher scores may be associated with worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in anger-hostility
To determine if the TP has an impact on anger-hostility (POMS sub-score) compared to placebo. Min 0, max 48, higher scores are associated with worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in vigor-activity
To determine if the TP has an impact on vigor-activity (POMS sub-score) compared to placebo. Min 0, max 32, higher scores are associated with better outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in confusion-bewilderment
To determine if the TP has an impact on confusion-bewilderment (POMS sub-score) compared to placebo. Min 0, max 28, and higher scores are associated with worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in depression-dejection
To determine if the TP has an impact on depression-dejection (POMS sub-score) compared to placebo. Min 0, max 60, and higher scores are associated with worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in tension-anxiety
To determine if the TP has an impact on tension-anxiety (POMS sub-score) compared to placebo. Min 0, max 60, higher scores are associated with worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in Overall Body Pain/Discomfort Scale
To determine if the TP has an impact on body pain and discomfort assessed by the Overall Body Pain/Discomfort Scale compared to placebo, which is a validated dually anchored Likert 10-point scale. Min value is 0, the max is 10, and a higher value is a worse outcome.
Time frame: Baseline, Month 1, Month 2, Month 3
Changes in foundation pain
To determine if the TP has an impact on foundation pain index which is calculated from urinalysis compared to placebo. Min 0 and Max 100, higher scores indicate worse outcomes.
Time frame: Baseline, Month 1, Month 2, Month 3

Secondary outcomes

Changes in AST as a marker of liver function
To determine if the TP has an impact on serum AST as a marker of liver function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in ALT as a marker of liver function
To determine if the TP has an impact on serum ALT as a marker of liver function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in alkaline phosphatase as a marker of liver function
To determine if the TP has an impact on serum alkaline phosphatase as a marker of liver function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in creatinine as a marker of kidney function
To determine if the TP has an impact on creatinine as a marker of kidney function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in potassium as a marker of kidney function
To determine if the TP has an impact on potassium as a marker of kidney function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in blood urea nitrogen as a marker of kidney function
To determine if the TP has an impact on blood urea nitrogen as a marker of kidney function assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in blood glucose
To determine if the TP has an impact on blood glucose assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in electrolyte balance
To determine if the TP has an impact on electrolyte balance assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in serum albumin
To determine if the TP has an impact on serum albumin assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in serum albumin/globulin ratio
To determine if the TP has an impact on serum albumin/globulin ratio assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in total serum bilirubin serum
To determine if the TP has an impact on total bilirubin assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in total serum protein
To determine if the TP has an impact on total serum protein assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3
Changes in blood urea nitrogen
To determine if the TP has an impact on blood urea nitrogen assessed using a comprehensive metabolic panel compared to placebo
Time frame: Baseline, Month 3

Study locations

1 site

University of South Carolina Sport Science Lab
Columbia, South Carolina 29208, United States

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Sep 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered: Dec 6, 2021
First posted: Jan 28, 2022
StartActual: Jan 18, 2022
Primary completionActual: Sep 30, 2022
CompletionActual: Oct 30, 2022
Last update: Nov 1, 2022

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05212402
Lead sponsor: University of South Carolina
Collaborators: Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
Responsible party: Shawn M. Arent (Professor, University of South Carolina) — Principal investigator
First posted: Jan 28, 2022
Start date: Jan 18, 2022
Primary completion: Sep 30, 2022
Completion: Oct 30, 2022
Last update: Nov 1, 2022

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabinol

Other studies from this sponsor

University of South Carolina →

Start the discussion